Successful treatment of resistant alopecia totalis with tofacitinib
Keywords:
Alopecia totalis, Tofacitinib, Hair loss, Janus kinase inhibitorAbstract
Alopecia Areata (AA) is one of the most common autoimmune diseases that causes non-scarring, patchy hair loss. The most severe type of Alopecia areata is alopecia totalis (AT). Affected patients have association of psychological disease and shown decreased quality of life. Despite the fact that there are several treatment options available for AA, most of them do not provide satisfactory results when it comes to AT. Despite the fact that there are a number of treatment options available for AA, the most of them do not provide satisfying results when it comes to AT. The disease is distinguished by the invasion of hair bulbs by activated T lymphocytes cells. The pathophysiology of alopecia areata reveals CD4 cell depletion. AA has hereditary correlations with genes of major his to compatibility complex (MHC). In recent years, multiple series, case reports, and small open-label trials have demonstrated the effectiveness of oral Janus kinase (JAK) inhibitors as a therapy for AT. One of the commonly used JAK inhibitor for the treatment of psoriatic and rheumatoid arthritis is tofacitinib. Here, we present a 21-year-old male patient who had effective treatment for Alopecia totalis with tofacitinib. The patient lost all of his but regained after six months of therapy, and there was no sign of a recurrence. The patient responded favourably to the therapy; by the fourth week, hair had begun to grow, and by the sixth month, complete regrowth had been achieved. There were no significant negative effects reported. For AT, tofacitinib may be a well-tolerated and effective therapy option; however, more research is required to determine its long-term effectiveness.References
Yu L, Yu H, Zhang S, Hao Y, Zhang S. Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal? Front Immunol. 2022;13:904156.
Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397-403.
Spano F, Donovan JC. Alopecia areata: Part 1: pathogenesis, diagnosis, and prognosis. Can Fam Physician. 2015;61(9):751-5.
Strazzulla LC, Wang EH, Avila L, Sicco KL, Brinster N, Christiano AM, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78(1):1-2.
Trüeb RM, Dias MF. Alopecia areata: a comprehensive review of pathogenesis and management. Clin Rev Allergy Immunol. 2018;54:68-87.
Kassira S, Korta DZ, Chapman LW, Dann F. Review of treatment for alopecia totalis and alopecia universalis. Int J Dermatol. 2017;56(8):801-10.
Zhou C, Li X, Wang C, Zhang J. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol. 2021;61(3):403-23.
de Jong A, Jabbari A, Dai Z, Xing L, Lee D, Li MM, et al. High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata. JCI Insight. 2018;3(19):e121949.
Zhang T, Nie Y. Prediction of the risk of alopecia areata progressing to alopecia totalis and alopecia universalis: biomarker development with bioinformatics analysis and machine learning. Dermatology. 2022;238(2):386-96.
Elsayed M, Al Otaibi L, Quraishy N, Yusufali A. A Novel Hope for Alopecia totalis Patients: Case Report. Dubai Med J. 2020;3(4):150-3.
Ahmed AM, Mokadem A, Abd El Fattah SM, Essawy AM, Zidan AA. An Overview about Alopecia Areata Etiopathogenesis, Diagnosis, and Management. Egypt J Hosp Med. 2023;92(1):37-43.
Shivanna CB, Shenoy C, Priya RA. Tofacitinib (selective Janus kinase inhibitor 1 and 3): a promising therapy for the treatment of alopecia areata: a case report of six patients. Int J Trichol. 2018;10(3):103.
Dai Z, Sezin T, Chang Y, Lee EY, Wang EH, Christiano AM. Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata. Front Immunol. 2022;13:955038.
Burroway B, Griggs J, Tosti A. Alopecia totalis and universalis long‐term outcomes: a review. J Eur Acad Dermatol Venereol. 2020;34(4):709-15.
Jabbari A, Sansaricq F, Cerise J, Chen JC, Bitterman A, Ulerio G, et al. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J Invest Dermatol. 2018;138(7):1539-45.
Shin JW, Huh CH, Kim MW, Lee JS, Kwon O, et al. Comparison of the treatment outcome of oral tofacitinib with other conventional therapies in refractory alopecia totalis and universalis: a retrospective study. Acta Derm Venereol. 2019;99(1):41-6.
